Novartis Investigative Site

Bilbao, Bizkaia 48013

1 studies enrolling now · 10 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, Autoimmunity, Inflammation, Chronic Myelogenous Leukemia, Early Breast Cancer, Giant Cell Arteritis (GCA), Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Polymyalgia Rheumatica, Psoriasis, Sjogren Syndrome, Sjogrens Syndrome

Studies at this site

• Secukinumab Open Label Roll-over Extension Protocol — Recruiting now
• Asciminib Roll-over Study — Recruiting now
• Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) — Running, not enrolling
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. — Running, not enrolling
• Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome — Completed
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) — Completed
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer — Running, not enrolling
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) — Completed
• Study of Secukinumab With 2 mL Pre-filled Syringes — Completed